BR112022003999A2 - Miméticos de hepcidina conjugados - Google Patents

Miméticos de hepcidina conjugados

Info

Publication number
BR112022003999A2
BR112022003999A2 BR112022003999A BR112022003999A BR112022003999A2 BR 112022003999 A2 BR112022003999 A2 BR 112022003999A2 BR 112022003999 A BR112022003999 A BR 112022003999A BR 112022003999 A BR112022003999 A BR 112022003999A BR 112022003999 A2 BR112022003999 A2 BR 112022003999A2
Authority
BR
Brazil
Prior art keywords
conjugated
hepcidin
mimetics
hepcidin mimetics
treatment
Prior art date
Application number
BR112022003999A
Other languages
English (en)
Inventor
Y Liu David
Thomas Bourne Gregory
Bachulal Modi Nishit
Roopa Taranath
Kumar Gupta Suneel
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of BR112022003999A2 publication Critical patent/BR112022003999A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

miméticos de hepcidina conjugados. a presente invenção fornece análogos de hepcidina e composições farmacêuticas relacionadas e seu uso no tratamento de policitemia vera.
BR112022003999A 2019-09-03 2020-09-03 Miméticos de hepcidina conjugados BR112022003999A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962895201P 2019-09-03 2019-09-03
US202062983515P 2020-02-28 2020-02-28
US202063020945P 2020-05-06 2020-05-06
US202063059747P 2020-07-31 2020-07-31
PCT/US2020/049244 WO2021046246A1 (en) 2019-09-03 2020-09-03 Conjugated hepcidin mimetics

Publications (1)

Publication Number Publication Date
BR112022003999A2 true BR112022003999A2 (pt) 2022-05-31

Family

ID=74681239

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003999A BR112022003999A2 (pt) 2019-09-03 2020-09-03 Miméticos de hepcidina conjugados

Country Status (11)

Country Link
US (2) US20220372099A1 (pt)
EP (1) EP4025592A4 (pt)
JP (1) JP2022546878A (pt)
KR (1) KR20220075343A (pt)
CN (1) CN114729022A (pt)
AU (1) AU2020343328A1 (pt)
BR (1) BR112022003999A2 (pt)
CA (1) CA3152789A1 (pt)
IL (1) IL291030A (pt)
MX (1) MX2022002633A (pt)
WO (1) WO2021046246A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2901704T3 (es) 2013-03-15 2022-03-23 Protagonist Therapeutics Inc Análogos de hepcidina y usos de los mismos
SG10201810321PA (en) 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US11845808B2 (en) 2020-01-15 2023-12-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2022109328A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
AU2022293672A1 (en) * 2021-06-14 2023-12-14 Protagonist Therapeutics, Inc. Hepcidin mimetics for treatment of hereditary hemochromatosis
WO2023150630A2 (en) * 2022-02-02 2023-08-10 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2023150618A2 (en) * 2022-02-02 2023-08-10 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2024011188A1 (en) * 2022-07-07 2024-01-11 Protagonist Therapeutics, Inc. Combination therapy for treatment of iron overload diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1826216A1 (en) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
IL144989A0 (en) 1999-03-17 2002-06-30 Novo Nordisk As Method for acylating peptides and novel acylating agents
US7094785B1 (en) * 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
ES2901704T3 (es) 2013-03-15 2022-03-23 Protagonist Therapeutics Inc Análogos de hepcidina y usos de los mismos
CN106456703A (zh) * 2014-04-07 2017-02-22 摩坚瑟生物技术股份有限公司 铁调素模拟肽及其用途
CN107075574A (zh) * 2014-06-27 2017-08-18 领导医疗有限公司 铁调素和微型铁调素类似物及其用途
WO2017068090A1 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3509621A4 (en) 2016-09-06 2020-06-17 La Jolla Pharmaceutical Company METHODS OF TREATING IRON OVERLOAD
WO2018128828A1 (en) * 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
WO2019157268A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Also Published As

Publication number Publication date
KR20220075343A (ko) 2022-06-08
CA3152789A1 (en) 2021-03-11
US20210061872A1 (en) 2021-03-04
AU2020343328A1 (en) 2022-04-07
EP4025592A4 (en) 2023-08-02
CN114729022A (zh) 2022-07-08
EP4025592A1 (en) 2022-07-13
JP2022546878A (ja) 2022-11-09
US20220372099A1 (en) 2022-11-24
IL291030A (en) 2022-05-01
WO2021046246A1 (en) 2021-03-11
MX2022002633A (es) 2022-06-02

Similar Documents

Publication Publication Date Title
BR112022003999A2 (pt) Miméticos de hepcidina conjugados
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
ECSP22012826A (es) Inhibidores de parp1
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2020001783A1 (es) Composiciones que comprenden microbiota coseleccionada y métodos para su uso
CL2019002470A1 (es) Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina.
MX2020003661A (es) Formas de dosificacion de liquidos, metodos de fabricacion y uso.
BR112017021688A2 (pt) composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
BR112021008873A8 (pt) Formulação
CL2019001129A1 (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y.
CL2023002946A1 (es) Tratamiento conjunto antineoplásico
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
CL2017003152A1 (es) Composiciones de hidroxipropil beta-ciclodextrina y métodos
MX2023001292A (es) Mimeticos de hepcidina conjugados.
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
BR112021008012A2 (pt) Conjugados de anticorpo de cisteína engenheirada-fármaco com ligantes contendo peptídeo
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
AR114780A1 (es) Formulaciones estables de inmunoconjugado anti-cd79b
CO2022000270A2 (es) Inhibidores de enzimas
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
CL2023003518A1 (es) Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1